An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The investigational drug, SAR236553/REGN727, reduced levels of LDL-C, or “bad,” cholesterol in 40%-72% of patients who were taking stable doses of statin drugs.

The drug could be important in helping patients reduce cholesterol levels further when they reach the limitations of what a statin drug can do, according to a press release.

The news has boosted Regeneron shares to a new 52-week high of $121.14, up more than 1%. Sanofy’s ADS are also up about 1% at $38.72.

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.

If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Thanks! We will redirect you shortly to the free report!

By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.